MARKET

ABUS

ABUS

Arbutus Biopharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.443
+0.003
+0.06%
Opening 11:45 09/23 EDT
OPEN
4.590
PREV CLOSE
4.440
HIGH
4.640
LOW
4.440
VOLUME
1.44M
TURNOVER
--
52 WEEK HIGH
5.87
52 WEEK LOW
2.430
MARKET CAP
440.55M
P/E (TTM)
-4.6707
1D
5D
1M
3M
1Y
5Y
Arbutus Appoints Lisa M. Caperelli as Vice President, Investor Relations
Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat corona...
GlobeNewswire · 2d ago
Catalyst watch for next week: Apple, Zoom Video, Palo Alto Networks in the spotlight; OPEC update
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a
Seekingalpha · 09/10 19:00
41 Stocks Moving In Friday's Mid-Day Session
Gainers
Benzinga · 09/10 16:23
IVERIC bio, Endo leads healthcare gainers; Apellis Pharmaceuticals, Mersana Therapeutics among major losers
Gainers: IVERIC bio (NASDAQ:ISEE) +56%, Endo (NASDAQ:ENDP) +46%, NGM Biopharmaceuticals (NASDAQ:NGM) +16%, Arbutus Biopharma (NASDAQ:ABUS) +15%, CareMax (NASDAQ:CMAX) +11%. Losers: Apellis Pharmaceuticals (NASDAQ:APLS) -50%, Mersana Therapeutics (NASDAQ:MR...
Seekingalpha · 09/10 15:09
CEI, CEMI and CBIO among pre market gainers
IVERIC bio (NASDAQ:ISEE) +65% Apellis' mixed eye-drug data turns out to be 'positive' for Iveric Bio Vince Holding (NYSE:VNCE) +22% on Q2 earnings. Affirm Holdings (NASDAQ:AFRM) +21% on Q4 earnings. Endo International (NASDAQ:ENDP) +18% settles New
Seekingalpha · 09/10 12:16
20 Stocks Moving in Friday's Pre-Market Session
Gainers IVERIC bio, Inc. (NASDAQ: ISEE) rose 29.6% to $11.26 in pre-market trading. Iveric Bio recently reported inducement grants under Nasdaq Listing Rule 5635(c)(4).
Benzinga · 09/10 11:02
48 Biggest Movers From Yesterday
Gainers
Benzinga · 09/10 09:16
Arbutus to Participate in Upcoming Investor Conferences
WARMINSTER, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (...
GlobeNewswire · 09/07 12:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ABUS. Analyze the recent business situations of Arbutus Biopharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ABUS stock price target is 5.90 with a high estimate of 10.00 and a low estimate of 3.500.
EPS
Institutional Holdings
Institutions: 124
Institutional Holdings: 31.14M
% Owned: 31.40%
Shares Outstanding: 99.16M
TypeInstitutionsShares
Increased
21
8.45M
New
19
807.85K
Decreased
24
3.20M
Sold Out
23
3.24M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.23%
Pharmaceuticals & Medical Research
+1.11%
Key Executives
Non-Executive Chairman/Independent Director
Frank Torti
President/Chief Executive Officer/Director
William Collier
Chief Financial Officer
David Hastings
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Elizabeth Howard
Chief Scientific Officer
Michael Sofia
Other
Michael McElhaugh
Other
Gaston Picchio
Independent Director
Daniel Burgess
Independent Director
Andrew Cheng
Independent Director
Richard Henriques
Independent Director
Keith Manchester
Independent Director
James Meyers
Independent Director
Eric Venker
No Data
  • All
  • Financials
  • Insiders
More
About ABUS
Arbutus Biopharma Corporation is a clinical-stage, biopharmaceutical company. The Company is focused primarily on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple product candidates with distinct mechanisms of action that have the potential to provide a curative regimen for chronic HBV infection. The Company has also initiated a drug discovery and development effort for treating coronaviruses, including COVID-19. The Company’s two lead product candidates are AB-729, its subcutaneously-delivered RNA interference (RNAi) product candidate that suppresses HBsAg expression, and AB-836, the Company’s next-generation oral capsid inhibitor that suppresses HBV DNA replication. AB-729 is in an ongoing Phase Ia/Ib clinical trial and a Phase IIa proof-of-concept clinical trial in collaboration with Assembly Biosciences, Inc.

Webull offers kinds of Arbutus Biopharma Corp stock information, including NASDAQ:ABUS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABUS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABUS stock methods without spending real money on the virtual paper trading platform.